Paul Tudor Jones's EXAS Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 14,928 shares of Exact Sciences Corporation (EXAS) worth $816,711, representing 0.00% of the portfolio. First purchased in 2014-Q1, this long-term strategic position has been held for 47 quarters.
Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in EXAS, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2022, adding 82,515 shares. Largest reduction occurred in Q4 2022, reducing 78,722 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Exact Sciences Corporation (EXAS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Exact Sciences Corporation (EXAS) Trades by Paul Tudor Jones
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2014 | +11,040 | New Buy | 11,040 | $14.13 |
| Q2 2014 | -11,040 | Sold Out | 11,040 | $0.00 |
| Q3 2014 | +18,511 | New Buy | 18,511 | $19.39 |
| Q4 2014 | -9,011 | Reduce 48.68% | 9,500 | $27.47 |
| Q1 2015 | -9,500 | Sold Out | 9,500 | $0.00 |
| Q1 2016 | +19,436 | New Buy | 19,436 | $6.74 |
| Q2 2016 | -19,436 | Sold Out | 19,436 | $0.00 |
| Q3 2016 | +32,756 | New Buy | 32,756 | $18.56 |
| Q4 2016 | -32,756 | Sold Out | 32,756 | $0.00 |
| Q2 2017 | +28,500 | New Buy | 28,500 | $35.37 |
| Q3 2017 | -28,500 | Sold Out | 28,500 | $0.00 |
| Q4 2017 | +5,357 | New Buy | 5,357 | $52.45 |
| Q1 2018 | +19,826 | Add 370.10% | 25,183 | $40.34 |
| Q2 2018 | +51,400 | Add 204.11% | 76,583 | $59.79 |
| Q3 2018 | -76,583 | Sold Out | 76,583 | $0.00 |
| Q1 2019 | +32,103 | New Buy | 32,103 | $86.63 |
| Q2 2019 | -32,103 | Sold Out | 32,103 | $0.00 |
| Q3 2019 | +57,690 | New Buy | 57,690 | $90.36 |
| Q4 2019 | -57,690 | Sold Out | 57,690 | $0.00 |
| Q1 2020 | +6,948 | New Buy | 6,948 | $58.00 |
| Q2 2020 | -6,948 | Sold Out | 6,948 | $0.00 |
| Q4 2020 | +36,256 | New Buy | 36,256 | $132.50 |
| Q1 2021 | -36,256 | Sold Out | 36,256 | $0.00 |
| Q3 2021 | +26,946 | New Buy | 26,946 | $95.45 |
| Q4 2021 | -15,512 | Reduce 57.57% | 11,434 | $77.84 |
| Q1 2022 | -6,475 | Reduce 56.63% | 4,959 | $69.97 |
| Q2 2022 | -4,959 | Sold Out | 4,959 | $0.00 |
| Q3 2022 | +87,474 | New Buy | 87,474 | $32.49 |
| Q4 2022 | -78,722 | Reduce 89.99% | 8,752 | $0.05 |
| Q1 2023 | +429 | Add 4.90% | 9,181 | $0.07 |
| Q2 2023 | -9,181 | Sold Out | 9,181 | $0.00 |
| Q1 2025 | +10,530 | New Buy | 10,530 | $43.29 |
| Q2 2025 | +37,530 | Add 356.41% | 48,060 | $53.14 |
| Q3 2025 | -33,132 | Reduce 68.94% | 14,928 | $54.71 |
Paul Tudor Jones's Exact Sciences Corporation Investment FAQs
Paul Tudor Jones first purchased Exact Sciences Corporation (EXAS) in Q1 2014, acquiring 11,040 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Exact Sciences Corporation (EXAS) for 47 quarters since Q1 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's largest addition to Exact Sciences Corporation (EXAS) was in Q3 2022, adding 87,474 shares worth $2.84 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 14,928 shares of Exact Sciences Corporation (EXAS), valued at approximately $816,711. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Exact Sciences Corporation (EXAS) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's peak holding in Exact Sciences Corporation (EXAS) was 87,474 shares, as reported at the end of Q3 2022. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.